Connie Matsui
Chairman at SUTRO BIOPHARMA, INC.
Net worth: 8 M $ as of 2024-03-30
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Gregory Gorgas | M | 61 | 19 years | |
| Michael LaBarre | M | 60 |
IDEC Pharmaceuticals Corp.
 IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 28 years |
| Susan Alexander | F | 67 |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 21 years |
| Stelios Papadopoulos | M | 74 |
Biogen Idec, Inc. (North Carolina)
 Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | 16 years |
| Jeffrey Henderson | M | 59 | 9 years | |
| Nicole LaBrosse | F | 41 | 9 years | |
| Mark Snyder | M | 57 | 2 years | |
| Jane Chung | F | 53 | 3 years | |
| Helen Torley | M | 61 | 10 years | |
| William Newell | M | 66 | 15 years | |
| James Panek | M | 71 | 4 years | |
| Heidi Hunter | F | 66 | 3 years | |
| Daniel Petree | M | 68 | - | |
| Bernadette Connaughton | F | 65 | 6 years | |
| Jon Wigginton | M | 62 | 4 years | |
| Akiko Miyashita | F | 68 | 2 years | |
| Nicki Vasquez | M | 61 | 9 years | |
| Douglas Blayney | M | 73 | 7 years | |
| Jason Baybutt | M | 52 | 2 years | |
| Michael Dybbs | M | 49 | 6 years | |
| Henry Heinsohn | M | - | - | |
| Gregory Reyes | M | 70 | 4 years | |
| Tamara Favorito | F | 65 | 3 years | |
| Linda Fitzpatrick | F | 67 | 16 years | |
| Edward Albini | M | 66 | 11 years | |
| Robert Emanuele | M | 69 | 7 years | |
| John Freund | M | 70 | 10 years | |
| Matthew Posard | M | 56 | 11 years | |
| Steven Kelly | M | 59 | 7 years | |
| Joseph Lobacki | M | 65 | 7 years | |
| Barbara Duncan | F | 59 | 1 years | |
| Tram Bui | F | - | 2 years | |
| Andy Yates | M | - | 3 years | |
| Werner Rubas | M | - | 3 years | |
| David Pauling | M | - | - | |
| Carlos Lugo | M | - | - | |
| Anne Borgman | M | 56 | 1 years | |
| Diana Landa | F | - | 4 years | |
| Regina Cheng | F | - | 4 years | |
| Craig Berman | M | - | 4 years | |
| Steve Knowles | M | - | 6 years | |
| Amy Marinne Fox | F | - | 4 years | |
| Hans-Peter Gerber | M | - | 1 years | |
| Michael Dambach | M | 57 | 17 years | |
| Steven D. Reich | M | - | 6 years | |
| Steve Michel | M | - | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter O’Brien | M | 45 | 5 years | |
| William Young | M | 79 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 11 years |
| William Rastetter | M | 75 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016.
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 19 years |
| Gregory Ian Frost | M | 52 | 16 years | |
| Robert W. Pangia | M | 72 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 24 years |
| John Dunn | M | 72 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 10 years |
| Craig Eric Schneier | M | 76 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 8 years |
| Kathryn Falberg | F | 63 | 9 years | |
| Jonathan Lim | M | 52 | 7 years | |
| Lynn Schenk | F | 79 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 25 years |
| Cecil B. Pickett | M | 78 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | 3 years |
| Mark Wiggins | M | 68 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA.
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 11 years |
| Peter Kellogg | M | 67 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | 7 years |
| Kenneth Kelley | M | 64 | 17 years | |
| Kurt Gustafson | M | 56 | 4 years | |
| Harry Leonhardt | M | 67 | 5 years | |
| Paul Clancy | M | 62 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 16 years |
| Robert A. Hamm | M | 72 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 7 years |
| Richard Miller | M | 73 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 18 years |
| William R. Rohn | M | 80 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 12 years |
| Bruce R. Ross | M | 83 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 13 years |
| David Ramsay | M | 59 | 12 years | |
| Masaru Matsuda | M | 53 | 3 years | |
| Alphonse Galdes | M | 71 | - | |
| Daniel Janney | M | 58 | - | |
| Arturo Molina | M | 65 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 12 years |
| James Tobin | M | 79 | 5 years | |
| Alan B. Glassberg | M | 87 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB)
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 12 years |
| John Cox | M | 61 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 14 years |
| Walter H. Bee | M | - | - | |
| Jean Bizzari | M | 69 | 9 years | |
| Lynne Sullivan | F | 58 | 10 years | |
| Gilmore O’Neill | M | 59 | 15 years | |
| Albert Kildani | M | - | - | |
| Samantha Truex | F | - | 8 years | |
| Homa Yeganegi | F | - | - | |
| Jim Mazzola | M | - | 3 years | |
| Brian Posner | M | 62 | 14 years | |
| Michael MacLean | M | 58 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 4 years |
| Shalini Sharp | F | 49 | 5 years | |
| Eric S. Hoffman | M | 54 | 5 years | |
| Hans-Peter Hasler | M | 68 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | 8 years |
| Phillip Schneider | M | 68 |
IDEC Pharmaceuticals Corp.
IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | 16 years |
| Michael Kelly | M | 67 | 2 years | |
| Thomas F. Keller | M | 92 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 11 years |
| John Stuart Patton | M | 77 | 25 years | |
| James L. Vincent | M | 84 | 12 years | |
| Mary L. Good | M | 93 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 10 years |
| Lawrence C. Best | M | 75 |
Biogen Idec New Ventures, Inc.
Biogen Idec New Ventures, Inc. Investment ManagersFinance Founded in 2004, Biogen Idec New Ventures is the corporate venture group of Biogen Idec, Inc. In 2003, Biogen and IDEC Pharmaceuticals merged to create Biogen Idec, Inc. (NASDAQ: BIIB) | 5 years |
| Faheem Hasnain | M | 65 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | 4 years |
| Jean Liu | F | 55 | 3 years | |
| Randal Kirk | M | 70 | 11 years | |
| Robert Engler | M | 79 | 11 years | |
| Joseph Mara | M | 49 | - |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Connie Matsui
- Personal Network
